

Accelerating speed of time to value in R&D

Large pharmaceutical companies account for almost twothirds of total pharma research and development (R&D) investments¹ and spent a record total of US\$161 billion in 2023—an increase of almost 50% since 2018.² As a percentage of companies' net sales, spending reached a historic high of 23.4%.³

Since 2010, Deloitte's series on Measuring the return from pharmaceutical innovation has provided insights into the productivity of biopharma R&D and has now evolved to include the top 20 pharma companies by R&D spend (determined in 2020).⁴ For this cohort, R&D spend increased 4.5% from 2022 to 2023, while the average R&D cost to progress an asset from discovery to launch remained flat in this period at US\$2.284 billion per asset.⁵

This year's modeling, based on a dataset that includes an expanded scope of assets and line extensions, shows the internal rate of return (IRR) rising to 4.1% in 2023 from 1.2% in 2022—the lowest point for the cohort since our analysis began (figure 1).⁶



Figure 1. Internal rate of return of the late-stage pipeline

Source: Deloitte, "Unleash AI's potential: Measuring the return from pharmaceutical innovation - 14th edition," 2024.

In 2024, ongoing regulatory changes and loss of exclusivity of an unprecedented number of highvalue assets are expected to challenge the existing biopharma operating model.⁷ Pricing pressures from the Inflation Reduction Act's (IRA's) health provisions are already impacting R&D decision-making and portfolio strategies.⁸ Ten R&D leaders interviewed by Deloitte expressed more concern about changing regulations than cycle times or R&D costs.⁹

Scientific and technological advancements present a significant opportunity for those willing to harness the power of innovation, but the rapid pace of innovation can also be a challenge.¹⁰ Advances in AI, including Generative AI (GenAI), have the potential to demystify complex disease biology, expedite drug discovery, cut study timelines, revitalize the clinical trial experience and improve regulatory success. Realizing productivity improvements and unleashing AI's value could provide new sources of value.¹¹

Not just speed to market, but accelerating time to value

Speed to market has long been a leading priority for drug developers to accelerate patient access to lifesaving therapies.¹² Since Deloitte first started analyzing pharmaceutical innovation in 2010, still only about one in ten new drugs entering human trials obtains regulatory approval.¹³ Despite many advances in science and technology, this remains one of the leading challenges for the biopharma industry.¹⁴

"When you're facing an illness like cancer or heart disease, you don't want therapies 20 years from now—you want them now."

—David Reese, Executive Vice President, Research and Development, Amgen ¹⁵ Speed to market is only part of a success formula; companies should also be looking at ways to accelerate time to value.¹⁶ Leading biopharma companies are adopting new GenAI/AI technologies and other data innovations across the value chain, while forming new partnerships, collaborating early with regulators, and outsourcing for cost and time savings.

"Twenty-five percent of our projects entail working with partners, which has doubled research productivity as measured by dollars spent per clinical candidate and doubled our first-in-human entries."

-Paul Hudson, CEO, Sanofi¹⁷

Adopting a more agile mindset

Accelerating people and processes

By adopting strategies to accelerate time to value, companies can start on their individual path to potential cost savings and competitive advantage¹⁸ even if small gains are made in each step of the process.¹⁹ With the pace and development of AIenabled digital solutions only expected to accelerate, leaders should start reengineering with an agile mindset.²⁰

Accelerating time to value in an agile manner means having the people and processes in place to change and adapt swiftly in response to market forces.²¹ Successful companies are building strategies to reduce the time it takes to advance across the stages of R&D, commercialization, and post-marketing surveillance.²² "We are applying speed levers in multiple areas, from digital technology and innovative study designs to regulatory partnerships. Our goal is to help each drug development team integrate as many of these levers as possible to accelerate progress."

--Kimberly Clemenson, Vice President, R&D Transformation, Amgen²³

Snackable AI for improving business functions

At the BioCentury China Healthcare Summit in late 2023, Sanofi CEO Paul Hudson discussed how Sanofi uses "snackable AI" to get rapid access to data by providing many people across the organization with "bits" of AI for real-time decision-making and reporting. He says snackable AI offers radical data transparency and may provide immediate and trustworthy feedback without hesitation or sugarcoating–unlike managers who may delay delivering data to leaders when uncomfortable with the results.²⁴

Use of AI in R&D expected to grow 106%

While the pharma industry is innovative in R&D, it is also true that it is often slow at embracing technological revolutions.²⁵ However, GenAl has brought more widespread attention to the current state of Al and jumpstarted many new initiatives.²⁶ Research shows that Al currently accounts for approximately 16% of drug discovery efforts and is



predicted to grow by 106% over the next three to five years.²⁷ It is the combination of domain specific LLMs, GenAI, AI/ML, deep learning, and data analytics that is positioned to accelerate time to value across biopharma R&D.

The R&D function represents the top value opportunity for large biopharma companies representing 30-45% of value creation. Al applied to novel drug identification and accelerating drug development could provide both cost savings and revenue uplift.²⁸

Combining next-generation AI technologies with rich multi-omics data may close the loop across the R&D pipeline with rapid, automated generation and testing of hypotheses from bench to bedside.²⁹ Currently, GenAI may reshape the way life sciences organizations decide:

- Which disease areas to invest in,
- Which targets to pursue, and
- Which molecules to develop.³⁰

Incorporating GenAl in R&D, from novel target identification to regulatory approval

Experts have ambitions to apply GenAl technologies to novel target identification through to regulatory approval, and into commercialization.³¹ To kickstart their GenAl programs, organizations should employ "no regrets bets" that can deliver value in a relatively short timeframe (figure 2).³² These types of low-risk activities can accelerate progress, while de-risking investments.³³

DESCRIPTION VALUE TO VALUE TO WHY THIS IS THE BUSINESS UNIT THE ENTERPRISE **NO REGRETS Research & Scientific literature** Development summarization GenAl can cut through research noise and go Generates easy-to-Greater productivity + Cost reduction straight to insights with consume summaries of from faster hypotheses + Revenue uplift minimal resource scientific literature testing investment Intelligent study deliverable authoring Companies have a Automate the drafting Greater speed massive treasure trove + Cost reduction of clinical study report from less rework and of past documents that + Cost avoidance (CSR) deliverables automated drafting can be tapped into to automate creation

Figure 2. GenAl's "no regrets bets" in R&D

Source: Deloitte, "Realizing Transformative Value from AI & Generative AI in Life Sciences," 2024.

The following model illustrates three horizons of innovation in pharma R&D with the development of GenAI (figure 3). Throughout the evolution of GenAI, experts say that keeping a human-in-the loop where possible will be critical to maximizing productivity gains without significant risks, even in high stakes applications.³⁴

Figure 3: R&D transformation horizon

Areas of Change	Horizon 1 Today	Horizon 2 18 Months	Horizon 3 5 Years
How Is data managed and accessed?	Disjointed ecosystem of non- standardized data sources aligned to specific business processes Example: RWE for omics analysis; CTMS for clinical study conduct processes etc.	Amazon-like marketplace where purpose-built R&D data products or extracts can be searched and accessed Example: Research scientists can search for biomarker analysis data from past studies clinical trials data and request access	A dynamic data fabric that seamlessly connects data assets across functions to provide a single source of truth <i>Example: Clinicians can readily leverage</i> <i>real-time data from safety, commercial,</i> <i>and regulatory systems to meet their</i> <i>business needs</i>
How are insights curated and consumed?	Insights are generated from discrete analytical models and interpreted by data analysts to support clinical processes Scientists manually review and synthesize scientific literature (e.g., publications, patents) to create research insights <i>Example: Clinical study managers rely on</i> <i>data analysts to contextualize outputs of site</i> <i>selection analytical models</i>	Business users leverage GenAl to interpret outputs of complex analytical models that provide them with more flexibility and context Scientists can access summary insights from vast amounts of scientific literature enabling them to rapidly adapt research priorities Example: Clinicians can interact with GenAl chatbots to understand population health insights to optimize inclusion criteria	 Insights are readily-embedded into business workflows with little to no-need for human intervention Insights from external research are rapidly contextualized and disseminated across the enterprise Example: Research, Clinical, Finance, Commercial, Regulatory teams are provided with contextualized impact summaries of a competitor's patent
How are research operations conducted?	Experiments are highly manual and expensive due to iterative hypothesis development and compute-intensive validation <i>Example: Scientists manually create and test</i> <i>hypothesis, going back to the drawing board</i> <i>only after confirming failed hypotheses</i>	Scientists use AI-powered simulations to parallelize generation, testing, and optimization of thousands of hypotheses <i>Example: Scientists generate 3D</i> <i>biomolecular structures by rapidly testing</i> <i>and optimizing new molecules to treat breast</i> <i>cancer</i>	Research scientists prioritize leads by amplifying decisions with impact on downstream functions <i>Example: Researchers prioritize leads for</i> <i>treating breast cancer based on likelihood</i> <i>of regulatory approval and commercial</i> <i>viability</i>
How are clinical trials managed?	Complex trial processes and systems result in highly manual, linear, and siloed decision-making leading to suboptimal outcomes Example: Disjointed decisioning around study design and site selection lead to expensive delays in trial execution	Clinical processes are streamlined & simplified through AI / GenAI automation to deliver efficiency and experience gains <i>Example: GenAI copilots optimize study</i> <i>design decisions by incorporating insights</i> <i>from downstream patient enrollment and</i> <i>site selection processes</i>	Clinical trials are autonomously run through GenAl copilots that optimize outcomes across the end-to-end value chain <i>Example: Real-time participant attrition</i> <i>insights generate recommendations to</i> <i>modify upstream study design choices</i>
How does R&D interact with other functions?	Operations within different part of R&D are often siloed and insights are not shared across all R&D teams Example: Clinical data and analytics are rarely readily available to upstream research scientists	Seamless data and insight connectivity enables greater collaboration across all R&D functions Example: Research, clinical, and regulatory teams work together to solve problems and create new products	Hyper-connected enterprise where all enterprise functions work together to optimize enterprise outcomes Example: R&D, regulatory, commercial, and manufacturing functions collaborate to seamlessly launch new drugs
How do R&D organizations navigate regulatory landscapes?	Diverse regulatory rules are manually interpreted by local market and process teams in non-standardized, highly manual review cycles <i>Example: Regulatory teams spend weeks</i> <i>manually reviewing new clinical regulations</i> <i>in EU and assessing impact on ongoing and</i> <i>upcoming trials</i>	R&D teams leverage GenAl capabilities at scale to automate monitoring, synthesis, and impact assessment of regulations <i>Example: GenAl copilots identify and</i> <i>synthesize trial diversity requirements in the</i> <i>US and flag impacted studies</i>	Business processes limit human error and regulatory cycle time by building AI-enabled regulatory checks into processes <i>Example: GenAI copilots ensure new protocols</i> <i>are compliant with the latest regulatory</i> <i>policies during the drafting process</i>

Source: Deloitte analysis

Low-hanging fruit, GenAl replacing many manual processes

Google demonstrated the capabilities of its multimodal platform, Gemini, to aid research scientists in extracting data from scientific literature, often an arduous, time-consuming process done by hand.³⁵ In one example, Gemini read through 200,000 papers, filtered relevant studies down to 250, extracted the key data needed, annotated, and created graphs—and the entire process took about an hour.³⁶ In the near term, the ability to access knowledge rapidly and transform manual processes opens up an opportunity for GenAl in clinical trials.³⁷

"The clinical trial space is an area where we have a lot of repetitive and very time-consuming tasks. GenAl is really a tool that enables an acceleration in some of these tasks, where before it would be a very manual prolonged process for both sponsors and sites."

- Silvia De Carvalho, Clinical Studies lead at AXON

To achieve the necessary increases in R&D productivity, some of the sweet spots are drug discovery and early clinical development, from target selection to clinical proof-of-concept.³⁹ Synthetic data is one way to accelerate access to data to start prototyping models quickly, and generative chemistry combined with a platform of tools and human expertise may help speed up drug design and identify better candidates. Work is being done with GenAI in de novo protein design, such as antibody design.⁴⁰

GenAl model, SyntheMol, creating recipes for chemists to synthesize drugs in the lab

Researchers at Stanford Medicine and McMaster University are utilizing a new GenAI model for synthesizing molecules, dubbed SyntheMol.⁴¹ The model created structures and chemical recipes for six novel drugs aimed at killing resistant strains of Acinetobacter baumannii, one of the leading pathogens leading to antibacterial resistancerelated deaths.

Older computational models were able to yield some results by sifting through 100 million known compounds. However, this only scratched the surface in finding all the chemical compounds that could have antibacterial properties—estimated as close to 10⁶⁰ possible druglike molecules. The work is being expanded with other research groups, using the model for drug discovery for heart disease and to create new fluorescent molecules for laboratory research.⁴²

While a number of biotech companies are developing Al-designed drug molecules, none have received US Food & Drug Administration (FDA) approval.⁴³ It will take time to collect and analyze the data needed to demonstrate the safety and efficacy of these drugs through clinical trials.⁴⁴

Accelerating clinical trials with GenAI

As it develops, GenAl offers several possibilities for accelerating clinical trials, including:

- Automating document generation activities to increase velocity,
- Increasing study retention by amplifying patient engagement, and
- Improving regulatory engagement with tailored submissions.⁴⁵

Tracking speed, productivity, quality, and sustainability of GenAI applications

Reviews of potential applications for GenAl along the R&D pipeline should consider linking strategic value to metrics in speed, quality, productivity, and sustainability.⁴⁶ Use cases that improve the quality of data, assets, and decision-making have the potential to reduce failure rates across R&D phases.⁴⁷

Productivity and quality may offer the largest gains provided by GenAI in the near term, followed by speed, then sustainability over the next decade.⁴⁸ Considering individual use cases along these metrics may help determine an optimal string-of-pearls strategy—where use cases are combined to unlock the full value of GenAl.⁴⁹ Strategic applications of Al can be found all across the R&D value chain (figure 4).

When developing the business case for investment in digital and AI, the short-term costs need to be balanced against the long- term efficiency gains. Executing large-scale strategies requires setting up a governance function for making investments, assessing value realized, and monitoring ethical and legal risks from the use of AI.⁵⁰

For more information on the string-of-pearls strategy, read the **Extracting value from Generative AI and emerging technologies** section of the 2024 Global Life Sciences Sector Outlook.

E		Role of Al	Value levers
	Drug repurposing	Perform meta-analysis of clinical trial and research data to generate high quality hypothesis for drug repurposing	Reduced pre-clinical costsReduced time to marketHigher NDAs
	Al-driven drug discovery	Optimize target and biomarker identification and shortlisting candidates while assessing toxicity and therapeutic efficacy	Improved clinical success rateLower failure ratesHigher number of NDAs
	Rapid design and setup	Automated protocol generation, drafting of study documents (consent form, agreements) and regulatory submissions	 Lower average protocol authoring time Lower average time to first enrollment
	Digital data flow	Collate and standardize trial data elements to create analysis-ready data sets and to auto-populate tables and charts in trial artifacts (e.g., case report forms)	Reduced total time per phaseOn-time database lockFaster documentation creation
	Regulatory intent and submission excellence	Identify regulatory requirements across geographies, generate drafts of dossiers, and understand competitor regulatory strategy	Higher regulatory success
	Participant experiences	Enhancing participant experiences with strategic nudges to revolutionize recruitment and retention strategies	 Reduced drop out rate Faster recruitment Lower terminations for insufficient recruitment

Figure 4. Strategic applications of AI across the R&D value chain

Source: Deloitte UK, "Unleash AI's potential - Measuring the return from pharmaceutical innovation," April 2024.

Setting near-term GenAl objectives

Small molecule de novo generation is already delivering value, and the next wave of opportunities being developed are in the clinical arena, from operations and delivery to patient experience.⁵¹ In the near term, organizations should look to organize data more effectively, in addition to identifying early wins from productivity gains across functions.⁵² The quality and comprehensiveness of proprietary data that these algorithms are trained on are expected to be a differentiator. As GenAl becomes a core capability within R&D data science teams, organizations should also have strategies in place for developing their future workforce.⁵³

Accelerating speed in clinical trials

The pace for scientific and technological advancements is accelerating, from gene therapy to AI, but challenges in clinical research remain, including:

- The ability to recruit and retain a representative patient population
- The delayed response to operational problems
- The reliance on incomplete or un-insightful data sources

Ultimately, transforming clinical trials could require companies to work in very different ways, drawing on change management skills as well as partnerships and collaborations. This may require companies to develop highly skilled interdisciplinary leadership and AI experts who can innovate, organize, and guide others as well as AI-friendly CEOs and board members to push for the adoption of AI.⁵⁴

Strategic CGT partnerships trigger speed to value

Discovering how fast novel treatments can reach rare disease patients

In late 2023, the US FDA approved the first cell and gene therapy (CGT) treatment using CRISPR geneediting technology to treat sickle cell disease—Vertex Pharmaceuticals' Casgevy.⁵⁵ The treatment is being viewed as a test case for how fast these trailblazing medicines can reach patients (in 2024, experts will be tracking the results).⁵⁶ Some suggest that if more than 2%, or about 2,000 US sickle cell patients, benefit from CGT over the next year, it may be a marker of progress for the disease. ⁵⁷ There are 100,000 sickle cell disease patients in the US.⁵⁸ Tracking the speed at which revolutionary medicines reach patients may provide new insights and value.⁵⁹

"I think this is a pivotal moment in the field. It's been really remarkable how quickly we went from the actual discovery of CRISPR, the awarding of a Nobel Prize, and now actually seeing it being an approved product."

- Alexis Thompson, M.D., Chief of the Division of Hematology at Children's Hospital of Philadelphia⁶⁰

The Casgevy approval was quickly followed by another CGT approval for sickle cell disease, Bluebird Bio's Lyfgenia.⁶¹ In 2023, Bluebird Bio said that its study for Lyfgenia was the longest follow-up of sickle cell patients to date—following 47 patients over 5 years⁶²—and the National Heart, Lung, and Blood Institute (NHLBI) points to its transparency and collaboration as laying the groundwork for other technologies to follow.⁶³ The company says a validated access and reimbursement strategy is driving a favorable insurance coverage landscape.⁶⁴

Successful partnerships involve a combination of commercial and R&D arrangements

What moves the needle for CGT investors after regulatory approvals is what happens when a company is closer to having a commercial product, according to Deloitte US' CGT Market Index research team.⁶⁵ Strategic partnerships top the list of triggers, with market cap increasing by as much as 140% for companies announcing partnership arrangements with another, typically large pharma company (figure 5).⁶⁶

Figure 5. Deloitte CGT Market Index™ value triggers

Limited number of triggers correlate with an increased market value for CGT companies, data as of 2023



Source: Deloitte US analysis

Research demonstrates that the most successful partnerships involve a combination of commercial and R&D arrangements, not one or the other. These partnerships typically combine the technological expertise of CGT companies with the asset development experience, clinical trial know-how, market access, and distribution channel infrastructure of larger companies.⁶⁷

On the other hand, manufacturing partnerships did not trigger positive results, while contract manufacturers did derive more value than a company undertaking construction of its own costly facility.⁶⁸ Overall, companies stringing together multiple milestones realized continued high-impact value creation multiples over those hitting just one milestone and then moving on.⁶⁹

Outsourcing for time and cost savings

Outsourcing is on the rise for both biotech⁷⁰ and pharma companies to accelerate speed to market.⁷¹ Like the semiconductor segment, the pharmaceutical ecosystem has a mature horizontal division model of drug discovery and manufacture by biotech and pharmaceutical companies (figure 6).⁷²





Figure 6. Horizontal division of roles in pharma

Source: Copyright © 2022 Kurata, Ishino, Ohshima, and Yohda, "CDMOs Play a Critical Role in the Biopharmaceutical Ecosystem," Frontiers in Bioengineering and Biotechnology, 21 March 2022.

As many pharma companies adopt digital practices to shorten development timelines and reduce R&D costs, more are forming strategic alliances, outsourcing, or acquiring early and late-stage capabilities. There appears to be proliferation of collaborative research agreements/partnerships in the early drug discovery and preclinical drug development stages. In clinical trials, patient recruitment and clinical lab and diagnostics testing areas are seeing more outsourcing.⁷³ The number of contract research organizations (CROs) are growing,⁷⁴ and pharma companies are turning to flexible manufacturing in response to changing regulatory and market needs.⁷⁵

Proliferation of CROs facilitate experimentation

CROs and other contract service firms allow chemical expertise to be acquired rather than developed, which may enhance speed to market.⁷⁶ These molecule-on-demand firms have altered experimentation as artificial intelligence and machine learning help to design new drugs.⁷⁷

The growth in CROs is behind a renaissance in small molecule discovery with developers learning novel ways to use small molecules to target disease.⁷⁸ In 2023, sales of the top 10 selling drugs were split 40/60 between small molecules and larger, more complicated biologics where sales were dominated by a few biologic blockbusters.⁷⁹

Globalization of contract development and manufacturing organizations (CDMOs)

Life sciences and medtech companies are considering new ways of working to help ensure product safety and quality without sacrificing speed. Companies adopting cutting-edge technologies, employing advanced process automation/continuous manufacturing, and incorporating real-time monitoring and modular facilities designs, may quickly and efficiently adapt production processes to accommodate varying product types, volumes, and customer demands.⁸⁰

While some pharma companies in Europe favor regional CDMO services for close proximity to markets, innovation capabilities, and talent, CDMO services are being globalized by China and India. These two countries are projected to experience the largest CAGR growth in the CDMO industry—9.63% in China and 11.34% in India.⁸¹

C "R" DMO outsourcing model emerges globally to accelerate therapies

As drug makers seek to increase efficiency and productivity and gain access to advanced technologies, there is a growing demand for outsourcing technology solutions that provide more integrated end-to-end services.⁸² Drug makers are starting to seek out contract research development manufacturing organizations (CRDMOs). These operators consider themselves science and technology platforms that also bring the "R," or research, into the CDMO mix.⁸⁴

CRDMO facilities are starting to spring up around the world—including in China, Singapore, the US, and Italy. By consolidating and unifying the CRO and CDMO models, companies see an opportunity to accelerate the time it takes to bring new therapies to market.

"Building end-to-end capabilities and offering integrated solutions in the small molecule space is our vision. Clients and the market want a one-stop shop and a partner who can take care of the entire project."

-Giovanni De Filippo, Fine Chemicals Sales & BD head, Angelini Pharma SpA⁸⁵

New drug approvals and launches

A total of 69 novel active substances (NASs) were launched globally in 2023,⁸⁶ led by the US, with 55 compared to 37 in 2022.⁸⁷ Over the past five years, NAS launches around the globe totaled 362.⁸⁸ The tally of NAS launches in China is on the rise, but an increasing number are not available outside China, reflecting an increasingly domestic industry.⁸⁹

China eclipsing Europe and gaining on the US in R&D

Clinical trial starts are increasingly global with Asia experiencing the largest growth in recent years. China moved ahead of Europe in NAS launches as well as in clinical trials to reach the number two spot behind the US globally.⁹⁰ While China's NAS launches are domestic, China's clinical trials are increasingly global.

Only about a third of all clinical trials are being held in the US as the US clinical research footprint shifts overseas.⁹¹ China is only a few points behind the US, with 28% of all clinical trial starts from Chinaheadquartered companies in 2023—a significant jump from only 3% a decade ago (figure 7).⁹²

Notably, China also reached the number two spot for worldwide R&D expenditures across all industries, surpassing the EU (17.5%) with 17.8%, mainly as a result of its tech sector.⁹³ For China's pharma companies, high expenditures on R&D and procurement are shrinking profit margins.⁹⁴

Figure 7. Number of Phase I to III trial starts based on company headquarter location, 2008-2023



Source: IQVIA, "Global trends in R&D 2024," 2024.

Currently, the US leads biopharmaceutical innovation, supported by its large domestic market, IP protections, limits on government drug price setting, supportive science policies, and supportive innovation clusters.⁹⁵ However, the US is experiencing rising drug pricing pressures and US policies may weaken foundational IP protections.⁹⁶

Critics point to lessons learned as a result of the US decline in semiconductors and telecommunications, where the US originally held leadership positions. Policy analysts suggest policymakers should not attack pharmaceutical companies but focus more on how to win the global battle for pharmaceutical sector competitiveness.⁹⁷

Funding biopharma R&D

How biopharma R&D unfolds depends on the ability to effectively partner across geographies and between the public and private sectors. This highly collaborative process can affect decision-making about R&D investments.⁹⁸ Ultimately, financing for R&D can play a major role in whether the medicines and treatments that patients need are developed.⁹⁹

Researchers recently explored how pharmaceutical R&D is financed and how this may evolve in the future.¹⁰⁰ Of the total US\$300 billion spent on pharmaceutical R&D, large pharmaceutical companies represent almost two-thirds of investments.¹⁰¹ Public and not-for-profit sectors contribute a quarter of the total (US\$75 billion).¹⁰² These essential scientific

advances may then flow downstream for private R&D sector investment.¹⁰³ Venture capital currently accounts for about a tenth of the total investment.¹⁰⁴

Calls for more research into drug development productivity/value creation

Some AI researchers say that more funding should go to academia to study ways to cut costs and improve pharmaceutical R&D productivity as there is scant research on how value is actually created.¹⁰⁵ The US Congressional Budget Office (CBO) also recently called out a need for more research.¹⁰⁶

The CBO uses a simulation model of drug development to analyze legislative proposals and incorporates feedback from academic and industry experts to inform its model. Life sciences and medtech leaders should be aware that the agency recently expressed interest in researching:

- How changes in the future profits of pharma companies might affect the development of drugs with differing characteristics (e.g., small and large molecules),
- How changes in the number of new drugs can affect health outcomes, and
- How policies—such as price negotiation or accelerated drug approvals—could affect companies' decisions about which indications to target for approval.¹⁰⁷

Contacts

Dawn Anderson Managing Director Deloitte United States dawanderson@deloitte.com

Andrew Bolt Partner Deloitte United States anbolt@deloitte.com

Kevin Dondarski Partner Deloitte United States kdondarski@deloitte.com

Colin Terry Partner Deloitte United Kingdom colterry@deloitte.co.uk

Interested in learning more about **Accelerating speed of time to value in R&D** and its impact on global life sciences? Check out these Deloitte publications:

Unleash Al's potential - Measuring the return from pharmaceutical innovation - 14th edition

Opportunities for improvement in early clinical development trials

Drug launch success

Endnotes

Accelerating speed of time to value in R&D

- "S. Marjanovic, S. Parkinson, R. Romanelli, and W. Phillips, "Understanding the financial ecosystem surrounding the development of medicines," Rand.
- 2. "Global Trends in R&D 2024," IQVIA, February 2024.
- 3. Ibid.
- 4. "Unleash Al's potential: Measuring the return from pharmaceutical innovation 14th edition," Deloitte, April 2024.
- 5. Ibid.
- 6. Ibid.
- 7. Ibid.
- "Inflation Reduction Act Already Impacting R&D," PhRMA, December 2022.
- 9. "Unleash Al's potential: Measuring the return from pharmaceutical innovation 14th edition," Deloitte, April 2024.
- 10. Ibid.
- 11. "Accelerating R&D to Speed Medicines to Patients," Amgen, 16 December 2021.
- D. Doleski, L. Chin, "When Speed to Market Counts," Pharmaceutical Engineering, 28 April 2023.
- "Intelligent clinical trials: Transforming through AI-enabled engagement," Deloitte UK, 2022.
- 14. D. Doleski, L. Chin, "When Speed to Market Counts," Pharmaceutical Engineering, 28 April 2023.
- 15. "Accelerating R&D to Speed Medicines to Patients," Amgen, 16 December 2021.
- 16. E. Grigul, "Demystifying Time-To-Value In Digital Commerce," Forbes, 27 July 2023.
- P. Hudson, "Sanofi CEO: AI promises a great era of drug discovery that could fundamentally change medicine-but only if we allow it to deliver," Fortune, 19 February 2024.
- D. Doleski, L. Chin, "When Speed to Market Counts," Pharmaceutical Engineering, 28 April 2023.
- 19. A. Roland, A. Baker, "A New Look at R&D Productivity," IQVIA, 2023.
- L. Merovitz, A. Heckman, "Agile change keeps pace with digital delivery," Deloitte, 22 February 2024.
- 21. https://www.forbes.com/sites/forbestechcouncil/2023/07/27/

demystifying-time-to-value-in-digitalcommerce/?sh=1ceb12512ae9

- E. Grigul, "Demystifying Time-To-Value In Digital Commerce," Forbes, 27 July 2023.
- 23. "Accelerating R&D to Speed Medicines to Patients," Amgen, 16 December 2021.
- 24. A. Zhavoronkov, "Can This Pharma CEO Change The Way Drugs Are Discovered, Developed, And Delivered With AI?," Forbes, 8 November, 2023.
- 25. P. Hudson, "The right way to bring Al into pharma," Stat News, 8 September, 2023.
- 26. M. Walsh, N. Mittal, "To Scale GenAl, Companies Need to Focus on 3 Factors," Harvard Business Review, 1 December 2023.
- A. Cronin, "Leveraging AI and ML in Drug R&D: Current and Future Impacts on the Life Sciences Industry," LifeSci Search, 9 October, 2023.
- 28. "Realizing Transformative Value from AI & Generative AI in Life Sciences," Deloitte, April 2024.
- G. Doron, S. Genway, M. Roberts, S. Jasti, "New Horizons: Pioneering Pharmaceutical R&D with Generative AI from lab to the clinic - an industry perspective." Arxiv, 21 December 2023.
- https://www2.deloitte.com/us/en/blog/health-care-blog/2023/ generative-ai-could-help-accelerate-clinical-development.html
- G. Doron, S. Genway, M. Roberts, S. Jasti, "New Horizons: Pioneering Pharmaceutical R&D with Generative AI from lab to the clinic - an industry perspective." Arxiv, 21 December 2023.
- 32. "Realizing Transformative Value from AI & Generative AI in Life Sciences," Deloitte, April 2024.
- 33. Ibid.
- 34. https://arxiv.org/pdf/2312.12482.pdf
- 35. "This is changing the way scientists research," Google, February 2024.
- 36. Ibid.
- G. Doron, S. Genway, M. Roberts, S. Jasti, "New Horizons: Pioneering Pharmaceutical R&D with Generative AI from lab to the clinic - an industry perspective." Arxiv, 21 December 2023.
- "Precision in practice: GenAl in clinical trials," Pharma Phorum, 3 January 2024.

- "How to improve R&D productivity: the pharmaceutical industry's grand challenge," Nature, 19 February 2010.
- 40. V. Levy, P. Lyons, "Can life sciences companies unlock the full value of GenAl?," Deloitte, 3 October 2023.
- R. Tompa, "Generative AI develops potential new drugs for antibiotic-resistant bacteria," Stanford Medicine, 28 March, 2024.
- 42. Ibid.
- 43. "What Al-Designed Drugs Have Been FDA-Approved?" Vial.
- 44. Ibid.
- 45. A. Bolt, A. Cheung, "Generative Al could help accelerate clinical development," Deloitte, 14 December 2023.
- 46. G. Doron, S. Genway, M. Roberts, S. Jasti, "New Horizons: Pioneering Pharmaceutical R&D with Generative AI from lab to the clinic - an industry perspective." Arxiv, 21 December 2023.
- 47. Ibid.
- 48. Ibid.
- 49. V. Levy, P. Lyons, "Can life sciences companies unlock the full value of GenAI?," Deloitte, 3 October 2023.
- 50. E. May, S. Nagpal, "Unleash Al's potential Measuring the return from pharmaceutical innovation," Deloitte, 26 April 2024.
- G. Doron, S. Genway, M. Roberts, S. Jasti, "New Horizons: Pioneering Pharmaceutical R&D with Generative AI from lab to the clinic - an industry perspective." Arxiv, 21 December 2023.
- 52. Ibid.
- 53. Ibid.
- 54. E. May, S. Nagpal, "Unleash Al's potential Measuring the return from pharmaceutical innovation," Deloitte, 26 April 2024.
- 55. B. Lovelace Jr., M. Kopf, "FDA approves cure for sickle cell disease, the first treatment to use gene-editing tool CRISPR," NBC News, 8 December 2023.
- 56. M. Aitken, "Outlook for 2024: 7 Key Indicators of Progress in the Life Sciences Sector," IQVIA, 5 January 2024.
- 57. Ibid.
- 58. Ibid.
- 59. Ibid.
- 60. B. Lovelace Jr., M. Kopf, "FDA approves cure for sickle cell disease,

the first treatment to use gene-editing tool CRISPR," NBC News, 8 December 2023.

- 61. M. Aitken, "Outlook for 2024: 7 Key Indicators of Progress in the Life Sciences Sector," IQVIA, 5 January 2024.
- "Long-term Follow-up Data From bluebird's Gene Therapy and Resolution of Vaso-Occlusive Events," bluebird bio, 9 December 2023.
- 63. "bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events," bluebird bio, 8 December 2023.
- 64. "bluebird bio provides update on commercial launch progress program milestones and 2024 financial outlook," Morningstar.
- 65. "Unlocking Value Drivers for Cell and Gene Therapy Companies," The Wall Street Journal CFO Journal, 12 December 2023.
- 66. Ibid.
- 67. Ibid.
- 68. Ibid.
- 69. Ibid.
- "CDMO Market Size & Share Analysis Growth Trends & Forecasts (2024 - 2029)," Modor Intelligence.
- 71. A. Buvailo, "The Increasing Role of CROs in the Pharmaceutical Industry, BioPharma Trend, 11 July 2023.
- 72. "CDMOs Play a Critical Role in the Biopharmaceutical Ecosystem," National Institute of Health, 21 March 2022.
- 73. M. Latey, D. Jones, "Five Predictions for the Biopharma and Biotech Industries in 2024," PPD, 30 November 2023.
- 74. "CRO Market Size & Share Analysis Growth Trends & Forecasts (2024 - 2029)," Modor Intelligence.
- 75. A. Kane, "CDMO 2.0: Three pharma industry trends for 2024 and beyond," Thermo Fisher, 25 January 2024.
- 76. "CRO Market Size & Share Analysis Growth Trends & Forecasts (2024 2029)," Modor Intelligence.
- L. Howes, "Is this a golden age of small-molecule drug discovery?" C&EN, 30 October 2023.
- "Small Molecule Drug Discovery Market Size & Share Analysis -Growth Trends & Forecasts (2024 - 2029)," Modor Intelligence.

- L. Howes, "Is this a golden age of small-molecule drug discovery?" C&EN, 30 October 2023.
- 80. A. Kane, "CDMO 2.0: Three pharma industry trends for 2024 and beyond," Thermo Fisher, 25 January 2024.
- "CDMO Market Size & Share Analysis Growth Trends & Forecasts (2024 - 2029)," Modor Intelligence.
- L. Garguilo, "Is Technology The New Science Of Outsourcing?" Outsourced Pharma, 4 May 2023.
- 83. Ibid.
- 84. ""CRDMO" the new business model for future of the (Bio)Pharma Industry," Angelini Pharma, 10 April 2022.
- 85. Ibid.
- 86. "Global Trends in R&D 2024," IQVIA, February 2024.
- M. Mishra, P. Jain, "US FDA approvals bounce back in 2023, sparking hopes of a biotech recovery," Reuters, 2 January 2024.
- 88. "Global Trends in R&D 2024," IQVIA, February 2024.
- 89. Ibid.
- 90. Ibid.
- 91. "Examination of Clinical Trial Costs and Barriers for Drug Development," ASPE, 24 July 2014.
- 92. "Global Trends in R&D 2024," IQVIA, February 2024.
- 93. T. Kawakami, "Chinese companies close R&D spending gap with U.S., led by Huawei," 5 February 2024.
- B. van Wyk, "China's pharma companies are spending big on R&D, but global success remains elusive," The China Project, 9 May 2022.
- S. Barbosu, "Not Again: Why the United States Can't Afford to Lose Its Biopharma Industry," Information Technology & Innovation Foundation, 29 February 2024.
- 96. Ibid.
- 97. Ibid.
- 98. https://www.rand.org/randeurope/research/projects/financialecosystem-underpinning-medicine-development.htm

99. "S. Marjanovic, S. Parkinson, R. Romanelli, and W. Phillips, "Understanding the financial ecosystem surrounding the development of medicines," Rand.

100.lbid.

101. lbid.

102. lbid.

103.Ibid.

104.Ibid.

- 105. https://www.forbes.com/sites/alexzhavoronkov/2023/08/09/616billion-per-drug-approval-almost-half-of-big-pharma-companieshit-negative-rd-productivity/?sh=704a23765447
- 106.P. Swagel, "A Call for New Research in the Area of New Drug Development," Congressional Budget Office, 20 December 2023.

107. Ibid.



About Deloitte's Global Life Sciences Sector Group

Together, advancing the business of science

Creating a health care ecosystem that provides quality, accessible care for all takes innovative leaders. Challenging the status quo requires guidance from a trusted team equally committed to health equity and transformation. Deloitte Health Care stands alongside those who stand for better, improving individual lives and the health of society. We help redefine the care journey by engineering digital strategies based on our deep experience and insights. We help accelerate action and create connections that empower a digitally enabled, equitable future of health.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited ("DTTL"), its global network of member firms, and their related entities (collectively, the "Deloitte organization"). DTTL (also referred to as "Deloitte Global") and each of its member firms and related entities are legally separate and independent entities, which cannot obligate or bind each other in respect of third parties. DTTL and each DTTL member firm and related entity is liable only for its own acts and omissions, and not those of each other. DTTL does not provide services to clients. Please see www.deloitte.com/about to learn more.

Deloitte provides industry-leading audit and assurance, tax and legal, consulting, financial advisory, and risk advisory services to nearly 90% of the Fortune Global 500® and thousands of private companies. Our professionals deliver measurable and lasting results that help reinforce public trust in capital markets, enable clients to transform and thrive, and lead the way toward a stronger economy, a more equitable society, and a sustainable world. Building on its 175-plus year history, Deloitte spans more than 150 countries and territories. Learn how Deloitte's approximately 415,000 people worldwide make an impact that matters at www.deloitte.com.

This communication contains general information only, and none of Deloitte Touche Tohmatsu Limited ("DTTL"), its global network of member firms or their related entities (collectively, the "Deloitte organization") is, by means of this communication, rendering professional advice or services. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser.

No representations, warranties or undertakings (express or implied) are given as to the accuracy or completeness of the information in this communication, and none of DTTL, its member firms, related entities, employees or agents shall be liable or responsible for any loss or damage whatsoever arising directly or indirectly in connection with any person relying on this communication. DTTL and each of its member firms, and the irrelated entities, are legally separate and independent entities.